GreenLight Biosciences (NASDAQ:GRNA) and PharmaCyte Biotech (OTCMKTS:PMCBD) Head to Head Survey
GreenLight Biosciences (NASDAQ:GRNA) and PharmaCyte Biotech (OTCMKTS:PMCBD) Head to Head Survey
GreenLight Biosciences (NASDAQ:GRNA – Get Rating) and PharmaCyte Biotech (OTCMKTS:PMCBD – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
綠光生物科學（NASDAQ：GRNA — 獲得評級）和藥劑生物技術（OTCMKTS：PMCBD-獲取評級）都是小型醫療公司，但哪個業務更好？我們將根據兩家企業的風險，估值，股息，機構所有權，分析師建議，盈利和盈利能力對比這兩家企業。
Risk & Volatility
風險及波動性
GreenLight Biosciences has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.
綠光生物科學的測試版為 1.48，表明其股價比標普 500 的波動性高 48%。相比之下，藥典生物技術的測試值為 0.27，表明其股票價格的波動性比標普 500 少 73％。
Profitability
盈利
This table compares GreenLight Biosciences and PharmaCyte Biotech's net margins, return on equity and return on assets.
此表格比較了 GreenLight 生物科學和藥典生物技術的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| GreenLight Biosciences | N/A | -195.71% | -45.30% |
| PharmaCyte Biotech | N/A | -49.09% | -43.39% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 綠光生物科學 | N/A | -195.71% | -45.30% |
| 藥典生物科技 | N/A | -49.09% | -43.39% |
Valuation and Earnings
估值及收益
This table compares GreenLight Biosciences and PharmaCyte Biotech's gross revenue, earnings per share (EPS) and valuation.
此表格比較了 GreenLight 生物科學和藥典生物技術的總收入、每股盈利（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GreenLight Biosciences | N/A | N/A | -$15.06 million | N/A | N/A |
| PharmaCyte Biotech | N/A | N/A | -$3.83 million | N/A | N/A |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 綠光生物科學 | N/A | N/A | -15.06 萬美元 | N/A | N/A |
| 藥典生物科技 | N/A | N/A | -383 萬美元 | N/A | N/A |
Analyst Recommendations
分析師推薦
This is a breakdown of recent ratings and target prices for GreenLight Biosciences and PharmaCyte Biotech, as provided by MarketBeat.
這是由 MarketBeat 提供的綠光生物科學和藥理生物技術的最新評分和目標價格的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GreenLight Biosciences | 0 | 0 | 3 | 0 | 3.00 |
| PharmaCyte Biotech | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 綠光生物科學 | 0 | 0 | 3 | 0 | 3.00 |
| 藥典生物科技 | 0 | 0 | 0 | 0 | N/A |
GreenLight Biosciences presently has a consensus target price of $4.50, indicating a potential upside of 798.38%. Given GreenLight Biosciences' higher probable upside, research analysts clearly believe GreenLight Biosciences is more favorable than PharmaCyte Biotech.
綠光生物科學目前的共識目標價為 4.50 美元，表明潛在的上行空間為 798.38%。鑑於 GreenLight 生物科學的可能上升空間較高，研究分析師清楚地認為綠光生物科學比藥學生物技術更有利。
Institutional & Insider Ownership
機構和內幕所有權
24.4% of GreenLight Biosciences shares are held by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are held by institutional investors. 30.3% of GreenLight Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
綠光生物科學股份中 24.4% 由機構投資者持有。相比之下，0.0% 的藥劑生物技術股份由機構投資者持有。GreenLight 生物科學股份的 30.3% 由公司內部人士持有。強大的機構所有權表明，大型資金經理，對沖基金和捐贈基金認為一家公司有望實現長期增長。
Summary
摘要
GreenLight Biosciences beats PharmaCyte Biotech on 5 of the 8 factors compared between the two stocks.
綠光生物科學在兩個股票之間的 8 個因素中有 5 個擊敗了藥理生物技術。
About GreenLight Biosciences
關於綠光生物科學
(Get Rating)
(取得評分)
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
綠光生物科學控股是一家生物技術公司，生產和銷售核糖核酸（RNA）產品，用於人類健康和農業應用。其對人體健康的產品包括 mRNA 疫苗和治療藥物；以及用於保護蜜蜂和農作物的農業 RNA 產品。該公司成立於 2008 年，總部位於馬薩諸塞州梅德福。
About PharmaCyte Biotech
關於藥典生物科技
(Get Rating)
(取得評分)
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.
PharhySyte 生物科技股份有限公司是一家臨床階段生物技術公司，致力於癌症和糖尿病治療的開發和商業化。它專注於一種專有的基於纖維素的活細胞封裝技術，稱為 Cell-in-a-Box，該技術將用作開發無法手術的胰腺癌和其他實體癌性腫瘤以及糖尿病治療的平台。該公司成立於 1996 年 10 月 28 日，總部位於加利福尼亞州拉古納山。
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收綠光生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 GreenLight 生物科學及相關公司的最新新聞和分析師評級的簡要每日摘要。